- Rapid alkaline phosphatase velocity (APV) predicted shorter OS and bone metastasis-free survival (BMFS) in patients with castration-resistant prostate cancer (CRPC).
Why this matters
- 12% of patients with organ-confined prostate cancer at initial presentation develop bone metastases (BM).
- <1% of these patients survive ≥5 y.
- Efficacy of PSA doubling time (PSADT) in predicting BM in patients with rising PSA is limited.
- Present findings confirm previous evidence of the benefit of APV+PSADT for risk stratification.
- Racial/ethnic composition of this study is more representative of the general US population than previous cohorts, making it more generalizable.
- Retrospective cohort study evaluated 89 patients with CRPC who received androgen deprivation therapy between 1989 and 2010.
- Funding: None disclosed.
- Faster APV significantly predicted shorter BMFS and OS (P=.0451 and P=.0109).
- In multivariate analysis, APV ≥5.42 U/L/y vs APV <5.42 U/L/y was strongly associated with BMFS (HR, 3.25; P=.027) and OS (HR, 4.47; P=.0052).
- PSADT<10 vs PSADT ≥10 mo was significantly associated with shorter BMFS (HR, 33.32; P<.0001) and OS (HR, 12.25; P<.0001)
- Small sample size.